A nanoemulsion/micelles mixed nanosystem for the oral administration of hydrophobically modified insulin

被引：0
作者：
Irene Santalices
Carlos Vázquez-Vázquez
Manuel J. Santander-Ortega
Victoria Lozano
Francisca Araújo
Bruno Sarmento
Neha Shrestha
Veronique Préat
Miguel Chenlo
Clara V. Alvarez
Federico Benetti
Juan Cuñarro
Sulay Tovar
Dolores Torres
María José Alonso
机构：
[1] University of Santiago de Compostela,Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)
[2] University of Santiago de Compostela,Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy
[3] University of Santiago de Compostela,Department of Physical Chemistry, Faculty of Chemistry
[4] University of Castilla-La Mancha,Cellular Neuroanatomy and Molecular Chemistry of Central Nervous System Group, School of Pharmacy
[5] University of Castilla-La Mancha,Regional Centre of Biomedical Research (CRIB)
[6] Instituto Nacional de Engenharia Biomédica (INEB),Instituto de Investigação E Inovação Em Saúde (i3S)
[7] Universidade Do Porto,Advanced Drug Delivery and Biomaterials
[8] Instituto de Investigacão E Formacão Avançada Em Ciências E Tecnologias da Saúde (CESPU),Neoplasia & Endocrine Differentiation Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)
[9] Université Catholique de Louvain,ECSIN
[10] Louvain Drug Research Institute,European Center for the Sustainable Impact of Nanotechnology
[11] University of Santiago de Compostela,undefined
[12] ECAMRICERT SRL,undefined
来源：
Drug Delivery and Translational Research | 2021年 / 11卷
关键词：
Oral; Peptide; Insulin; Nanocarrier; Nanoemulsion; Micelles;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：524 / 545
页数：21
相关论文
共 393 条
  • [1] Lau JL(2018)Therapeutic peptides: Historical perspectives, current development trends, and future directions Bioorganic Med Chem 26 2700-2707
  • [2] Dunn MK(2019)Non-invasive delivery strategies for biologics Nat Rev Drug Discov 18 19-40
  • [3] Anselmo AC(2019)Oral delivery of biologics for precision medicine Adv Mater 1901935 1-27
  • [4] Gokarn Y(2016)Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials Adv Drug Deliv Rev 106 223-241
  • [5] Mitragotri S(2020)Advances in oral peptide therapeutics Nat Rev Drug Discov 19 277-289
  • [6] Durán-Lobato M(2016)Oral delivery of peptides: opportunities and issues for translation Adv Drug Deliv Rev 106 193-195
  • [7] Niu Z(2012)A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial J Bone Miner Res 27 1821-1829
  • [8] Alonso MJ(2015)Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial J Clin Endocrinol Metab 100 1699-1708
  • [9] Aguirre TAS(2020)Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist Diabetes Technol Ther 22 10-18
  • [10] Teijeiro-Osorio D(2004)The physiological rationale for oral insulin administration Diabetes Technol Ther 6 510-517
12345678910